Protalix BioTherapeutics, Inc. (PLX)Healthcare | Biotechnology | Hackensack, United States | NYSE American
2.39 USD
-0.05
(-2.049%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:21 a.m. EDT
The investment case here is a study in contrasts between explosive recent growth and a precarious historical trajectory. Fundamentally, the company is firing on all cylinders with 234% revenue growth in the latest quarter, robust operating margins above 60%, and a return on equity nearing 27%. The balance sheet is surprisingly healthy for a biotech, carrying minimal debt against substantial cash reserves. However, the long-term price history tells a different story; despite the recent recovery, the stock has been down nearly 78% over the last nine years, reflecting a long struggle to prove its commercial thesis. The current price action shows a slight upward lean, trading above its 50-day moving average, which aligns with the improving fundamentals. Yet, the statistical forecast models remain neutral, capturing the uncertainty inherent in the sector. With no dividend to provide income, the entire return proposition relies on the continued execution of its pipeline and the eventual resolution of the long-term valuation discount. It is a high-risk, high-reward speculative play on a turnaround story that has finally found its footing. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.052452 |
| AutoETS | 0.053228 |
| MSTL | 0.053712 |
| AutoTheta | 0.096104 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.68 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.218 |
| Excess Kurtosis | -0.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.615 |
| Revenue per Share | 0.963 |
| Market Cap | 192,566,224 |
| Trailing P/E | 12.58 |
| Forward P/E | 3.85 |
| Beta | 0.00 |
| Profit Margins | 20.07% |
| Website | https://www.protalix.com |
As of July 11, 2026, 4:21 a.m. EDT: Speculators are positioning for significant volatility rather than a specific directional move. There is heavy open interest in out-of-the-money calls at the $5.0 strike across multiple expirations, suggesting a speculative bet on a massive upside event or binary outcome. Conversely, put writers are accumulating significant protection at the $2.0 strike, creating a floor around current prices. The implied volatility is elevated on both sides, indicating the market expects a wide range of outcomes.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.7183099 |
| Address1 | 2 University Plaza |
| Address2 | Suite 100 |
| All Time High | 912.5 |
| All Time Low | 0.7 |
| Ask | 2.38 |
| Ask Size | 2,200 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 732,360 |
| Average Daily Volume3 Month | 728,877 |
| Average Volume | 728,877 |
| Average Volume10Days | 732,360 |
| Beta | -0.002 |
| Bid | 0.0 |
| Bid Size | 1,600 |
| Board Risk | 7 |
| Book Value | 0.834 |
| City | Hackensack |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.39 |
| Current Ratio | 3.153 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.48 |
| Day Low | 2.39 |
| Debt To Equity | 12.615 |
| Display Name | Protalix BioTherapeutics |
| Dividend Date | 1,576,800,000 |
| Earnings Call Timestamp End | 1,778,673,600 |
| Earnings Call Timestamp Start | 1,778,673,600 |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | 21,314,000 |
| Ebitda Margins | 0.27905 |
| Enterprise To Ebitda | 7.036 |
| Enterprise To Revenue | 1.963 |
| Enterprise Value | 149,964,224 |
| Eps Forward | 0.62 |
| Eps Trailing Twelve Months | 0.19 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.1052 |
| Fifty Day Average Change | 0.28480005 |
| Fifty Day Average Change Percent | 0.13528408 |
| Fifty Two Week Change Percent | 71.830986 |
| Fifty Two Week High | 3.19 |
| Fifty Two Week High Change | -0.79999995 |
| Fifty Two Week High Change Percent | -0.25078368 |
| Fifty Two Week Low | 1.36 |
| Fifty Two Week Low Change | 1.0300001 |
| Fifty Two Week Low Change Percent | 0.757353 |
| Fifty Two Week Range | 1.36 - 3.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 895,239,000,000 |
| Float Shares | 77,447,074 |
| Forward Eps | 0.62 |
| Forward P E | 3.8548388 |
| Free Cashflow | 6,783,125 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 226 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.45236 |
| Gross Profits | 34,552,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03878 |
| Held Percent Institutions | 0.21326 |
| Implied Shares Outstanding | 80,571,642 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,576,800,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey. |
| Long Name | Protalix BioTherapeutics, Inc. |
| Market | us_market |
| Market Cap | 192,566,224 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_941520 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 15,332,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 196,594,806 |
| Number Of Analyst Opinions | 2 |
| Open | 2.45 |
| Operating Cashflow | 15,090,000 |
| Operating Margins | 0.62654996 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 201 696 9345 |
| Previous Close | 2.44 |
| Price Hint | 4 |
| Price To Book | 2.8657076 |
| Price To Sales Trailing12 Months | 2.5211272 |
| Profit Margins | 0.20073 |
| Quick Ratio | 1.972 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.05 |
| Regular Market Change Percent | -2.04918 |
| Regular Market Day High | 2.48 |
| Regular Market Day Low | 2.39 |
| Regular Market Day Range | 2.39 - 2.48 |
| Regular Market Open | 2.45 |
| Regular Market Previous Close | 2.44 |
| Regular Market Price | 2.39 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 485,476 |
| Return On Assets | 0.14038 |
| Return On Equity | 0.27271998 |
| Revenue Growth | 2.337 |
| Revenue Per Share | 0.963 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 80,571,642 |
| Shares Percent Shares Out | 0.0442 |
| Shares Short | 3,558,923 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,935,161 |
| Short Name | Protalix BioTherapeutics, Inc. |
| Short Percent Of Float | 0.046 |
| Short Ratio | 5.12 |
| Source Interval | 15 |
| State | NJ |
| Symbol | PLX |
| Target High Price | 12.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 51,083,000 |
| Total Cash Per Share | 0.634 |
| Total Debt | 8,481,000 |
| Total Revenue | 76,381,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.19 |
| Trailing P E | 12.578948 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.21245 |
| Two Hundred Day Average Change | 0.17755008 |
| Two Hundred Day Average Change Percent | 0.080250435 |
| Type Disp | Equity |
| Volume | 485,476 |
| Website | https://www.protalix.com |
| Zip | 7,601 |